Results 21 to 30 of about 5,281 (177)
Experience with canakinumab in a patient with gout and IgA nephropathy
Современная ревматология, 2019 The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj +1 more source
Kidney & Blood Pressure Research, 2018 Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano +5 more
doaj +1 more source
PLoS ONE, 2019 Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj +1 more source
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +1 more source
The impact of urate-lowering therapy on kidney function (IMPULsKF)
Počki, 2017 The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (
D.D. Ivanov
doaj +1 more source
Arthritis Research & Therapy, 2022 Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life.
John K. Botson +5 more
doaj +1 more source
Personalized Medicine of Urate-Lowering Therapy for Gout
, 2020 Gout is a common and complex form of arthritis that is characterised with hyperuricaemia. It is required urate-lowering therapy (ULT) for lifelong management. ULT includes decreasing uric acid product in serum, increasing renal urate excretion and promoting uric acid to allantoin for excretion.
Zhang, Y, Yan, D
openaire +4 more sources
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? [PDF]
Exploration of Musculoskeletal DiseasesCo-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares
Edward Roddy +2 more
doaj +1 more source
Comparison Between Early-Onset and Common Gout: A Systematic Literature Review
Rheumatology and Therapy, 2023 Introduction Gout is an inflammatory, metabolic disease associated with a high comorbidity burden including cardiovascular disease, hypertension, type 2 diabetes, hyperlipidemia, renal disease, and metabolic syndrome.
Anthony J. Amatucci +3 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Hyperuricemia is very common in patients with chronic kidney disease (CKD); the role of hyperuricemia in the occurrence and progression of kidney disease remains an interesting and unresolved issue for nephrologists, and whether urate ...
Xiang Liu +7 more
doaj +1 more source